Clinical Trials Logo

PD-1 Antibody clinical trials

View clinical trials related to PD-1 Antibody.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05156788 Active, not recruiting - Clinical trials for Biliary Tract Cancer

Tislelizumab(Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Start date: December 12, 2021
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess the R0 resection rate of tislelizumab combined with Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally advanced BTC.

NCT ID: NCT03668496 Active, not recruiting - Chemotherapy Effect Clinical Trials

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

Start date: November 9, 2018
Phase: Phase 3
Study type: Interventional

This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with stage IV squamous non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to compare the efficacy and safety of SHR-1210 + carboplatin + paclitaxel with placebo + carboplatin + paclitaxel in study population in China. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.